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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN UNTREATED
FIRST RELAPSE (REL1) OR FOLLOWING RE-INDUCTION CHEMOTHER-
APY (CT) FOR PATIENTS (PTS) WITH ACUTE MYELOGENOUS LEUKE-
MIA (AML)
Pornvipavee, R.; Dierkhising, R.A.; Elliott, M.A.; Hogan, W.J.; Kre-
mers, W.K.; Letendre, L.; Pedersen, R.A.; Tefferi, A.; Litzow, M.R.
Mayo Clinic College of Medicine, Rochester, MN.
The timing of ASCT for AML after ﬁrst relapse is controversial.
The purpose of this study was to review our results in AML pts in
ﬁrst relapse by comparing outcomes between pts taken directly to
ASCT and pts receiving re-induction chemotherapy prior to
ASCT. Between January 1990 and March 2003, 37 pts with AML
in REL1 or CT underwent ASCT. Survival was analyzed using the
Kaplan-Meier (KM) methodology with statistical comparisons us-
ing the log-rank test. Univariate predictors of survival were exam-
ined using Cox proportional hazard models. Of the 37, 25 and 12
pts underwent ASCT at CT and REL1 (median age 46 vs 42 years),
respectively. There was only 1 pt in the CT group who had
refractory disease. In the CT group, 18 pts (72%) and 7 pts (28%)
had stem cells harvested during CR1 and CR2, respectively. In the
REL1 group, all pts had stem cells harvested in CR1. Thirty of 37
pts received cyclophosphamide and total body irradiation (Cy/
TBI) for conditioning and the remainder received busulfan and
cyclophosphamide (Bu/Cy). There were no statistically signiﬁcant
differences in the baseline characteristics between the two groups.
The percentage of bone marrow blasts at ﬁrst relapse was increased
in the CT versus the REL1 group (median 40% vs 15%, p0.06).
KM analysis showed that there was no signiﬁcant difference be-
tween the two groups in time to neutrophil and platelet engraft-
ment. The REL1 group had a signiﬁcantly shorter time to relapse
than CT. The CT group had signiﬁcantly higher DFS than REL1
and a trend toward better OS with no difference in TRM. The
Table details estimated probabilities of these endpoints. Univariate
Cox proportional hazard analysis for overall survival showed that
younger age at diagnosis and transplantation, unfavorable cytoge-
netic abnormalities at diagnosis and relapse were signiﬁcantly as-
sociated with a higher risk of death. Higher percentage of blasts in
bone marrow at ﬁrst relapse and shorter duration of CR1 were not
signiﬁcantly associated with death. In a multivariate model, only
unfavorable cytogenetic abnormalities at ﬁrst relapse were signif-
icantly associated with an increase risk of death. Although OS
between CT and REL1 groups was not signiﬁcantly different, the
time to relapse and DFS were signiﬁcantly longer for the CT
group. Although retrospective and limited by selection bias, this
study suggests that there may be an advantage for re-induction
chemotherapy for AML in ﬁrst relapse before ASCT.
REL1
Post
CT
p
value*
Probability of Relapse (%) 0.0075
1 year 83.3 45.8
5 years 83.3 59.9
Median time to relapse (mos) 6.1 13.7
Overall Survival (OS) (%) 0.09
1 year 41.7 68.0
5 years 8.3 40.8
Median time of OS (mos) 8.7 17.9
Disease free survival (DFS) (%) 0.006
1 year 16.7 52.0
5 years 8.3 39.0
Median time of DFS (mos) 6.1 13.7
Transplant related mortality (TRM) (%) 0.50
1 year 0 4.0
*Log rank test comparing distribution of event times over multiple
comparisons.
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HIGH AVIDITY CYCLIN E1-DERIVED PEPTIDE-SPECIFIC CTL KILL LYM-
PHOID LEUKEMIA CELLS AND CROSS-RECOGNIZE A HOMOLOGOUS
CYCLIN E2-DERIVED PEPTIDE
Kondo, Y.; Wieder, E.; Lu, S.; Molldrem, J.J. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
Using a similar strategy that was used to identify PR1 as a
leukemia-associated antigen (LAA), we identiﬁed two homologous
HLA-A2-restricted peptides from cyclin E1 (CCNE1M) and cy-
clin E2 (CCNE2L) that could be used to elicit peptide-speciﬁc
CTL from healthy donors. The two peptides differ by a single
amino acid at position 7 and have equal binding afﬁnity for HLA-
A2, and each elicited peptide-speciﬁc CTL with equal efﬁciency.
Because each CCNE1M- and CCNE2L-CTL clone, derived from
limiting dilution, cross-recognized the other homologous peptide,
we hypothesized that each clone would efﬁciently kill leukemia that
over-expressed either or both CCNE1 and CCNE2 proteins.
Sorted high avidity CTL showed higher speciﬁc lysis of peptide-
pulsed T2 than did low avidity CTL (38.8% vs 31.9% speciﬁc lysis,
respectively, at E:T 10:1, p  0.02). The ﬂuorescence decay of
tetramer dissociation (ln (peptide/HLA-A2 tetramer)) over time
was linear for each clone, showing that avidity was proportional to
TCR afﬁnity and tetramer dissociation t1/2 was determined based
on ﬁrst order kinetics. CCNE1M-CTL had higher afﬁnity for
CCNE1M/HLA-A2 (CCNE1/A2, t1/284.5 min; CCNE2/A2,
t1/225.3 min) and preferentially killed CCNE1M-pulsed T2
cells (CCNE1, 56.9% vs CCNE2, 38%, respectively, at E:T 10:1).
CCNE2L-CTL also had higher TCR afﬁnity for CCNE1M/
HLA-A2 (CCNE1/A2, t1/229.5 min; CCNE2/A2, t1/210.7
min), but showed only slightly higher speciﬁc lysis of CCNE1M-
pulsed T2 cells (CCNE1, 49.3% vs CCNE2, 44.2% speciﬁc lysis,
respectively, at E:T 10:1). Each clone speciﬁcally lysed HLA-A2
T-ALL leukemia cells in proportion to both CCNE1 and CCNE2
protein overexpression (CCNE1M-CTL, R20.89; CCNE2L-
CTL, R20.88) in an HLA-A2-restricted manner. Both the high
and low afﬁnity clones showed equal lysis of T-ALL cells that
expressed large amounts of each protein (CCNE1M-CTL, 24.3%
vs CCNE2L-CTL , 23.8%, at E:T 10:1). However, high afﬁnity
CCNE1M-CTL killed T-ALL cells signiﬁcantly better than low
afﬁnity CCNE2L-CTL (16.8% vs 6.6% lysis, respectively, at E:T
10:1) when the T-ALL expressed a 2.5-fold lower amount of both
CCNE1 and CCNE2 proteins. We conclude that the CCNE1M
and CCNE2L homologous self-peptides are lymphoid LAA. Fur-
thermore, while the higher TCR afﬁnity of CCNE1M-CTL sug-
gests that the CCNE1M peptide is the more dominant epitope,
ultimate target susceptibility is enhanced due to degeneracy of the
resulting CTL clones against homologous peptide epitopes.
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NON-MYELOABLATIVE CONDITIONING FOR ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MY-
ELOID LEUKEMIA. THE IMPACT OF THE REMISSION STATUS
Gutierrez-Aguirre, C.H.; Cantu-Rodriguez, O.G.; Gonzalez-LLano,
O.; Salazar-Riojas, R.; Martinez-Gonzalez, O.L.; Jaime-Perez, J.C.;
Gomez-Almaguer, D. Hospital Universitario Dr. Jose´ E. Gonza´lez,
U.A.N.L., Monterrey, Nuevo Leo´n, Mexico.
Background: Multicentre randomized trials have shown that
allogeneic hematopoietic stem cell transplantation (HSCT) is the
most effective strategy for preventing relapse in patients in ﬁrst
complete remission (CR) of acute myeloblastic leukemia (AML),
offering up to 50% disease-free survival. However in adult patients
with good risk AML, allogeneic HSCT is usually indicated in
second complete remission or ﬁrst untreated relapse. We analyzed
the outcome of 16 AML patients who received a reduced intensity
conditioning regimen for allogeneic HSCT in ﬁrst or second
remission. Patients and Methods: Sixteen AML patients (1 M1, 8
M2, 3 M3, 2 M4 and 2 M5), 9 in ﬁrst CR (FCR) and 7 in second
CR (SCR) were included. All patients received Busulfan 4 mg/kg/
d/2 days, Fludarabine 30 mg/m2/d/3 days and cyclophosphamide
350 mg/m2/d/3 days as conditioning regimen. The median age was
32 years (range 3–56) in both groups. The source of hematopoietic
stem cells (HSC) was peripheral blood and donors were HLA
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